*The AIB1/NCOA3/SRC-3 Oncogene DOI: http://dx.doi.org/10.5772/intechopen.80925*

*Oncogenes and Carcinogenesis*

DOI: 10.1128/MCB.00336-06

10.1038/364259a0

1999;**19**:8226-8239

[16] Coulthard VH, Matsuda S, Heery DM. An extended LXXLL motif sequence determines the nuclear receptor binding specificity of TRAP220. Journal of Biological Chemistry. 2003;**278**:10942-10951. DOI:

10.1074/jbc.M212950200

10.1210/mend.15.6.0649

M004228200

[18] Koh SS, Chen D, Lee YH,

[17] Bramlett KS, Wu Y, Burris TP. Ligands specify coactivator nuclear receptor (NR) box affinity for

estrogen receptor subtypes. Molecular Endocrinology. 2001;**15**:909-922. DOI:

Stallcup MR. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. Journal of Biological Chemistry. 2001;**276**:1089-1098. DOI: 10.1074/jbc.

[19] Spencer TE, Jenster G, Burcin MM, Allis CD, Zhou J, Mizzen CA, et al. Steroid receptor coactivator-1 is a histone acetyltransferase. Nature. 1997;**389**:194-198. DOI: 10.1038/38304

[20] Reiter R, Wellstein A, Riegel AT. An isoform of the coactivator AIB1 that increases hormone and growth factor

Cellular Biology. 2007;**27**:1296-1308.

sensitivity is overexpressed in breast cancer. Journal of Biological Chemistry. 2001;**276**:39736-39741. DOI: 10.1074/

[21] List HJ, Reiter R, Singh B, Wellstein A, Riegel AT. Expression of the nuclear

coactivator AIB1 in normal and malignant breast tissue. Breast Cancer Research and Treatment. 2001;**68**:21-28

[22] Chien CD, Kirilyuk A, Li JV, Zhang W, Lahusen T, Schmidt MO, et al. Role of the nuclear receptor coactivator AIB1-Delta4 splice variant in the control of gene transcription. The Journal of Biological Chemistry. 2011;**286**:26813-26827. DOI: 10.1074/

[23] Zhang A, Yeung PL, Li C-W, Tsai S-C, Dinh GK, Wu X, et al. Identification of a novel family of ankyrin repeats containing cofactors for p160 nuclear receptor coactivators. Journal of Biological Chemistry. 2004;**279**:33799-33805. DOI: 10.1074/

[24] Garee JP, Chien CD, Li JV, Wellstein A, Riegel AT. Regulation of HER2 oncogene transcription by a multifunctional coactivator/corepressor complex. Molecular Endocrinology. 2014;**28**:846-859. DOI: 10.1210/

[25] Long W, Yi P, Amazit L, LaMarca HL, Ashcroft F, Kumar R, et al. SRC-3Δ4 mediates the interaction of EGFR with FAK to promote cell migration. Molecular Cell. 2010;**37**:321-332. DOI: 10.1016/j.

[26] Yoshida H, Liu J, Samuel S, Cheng W, Rosen D, Naora H. Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells. Molecular and Cellular Endocrinology. 2005;**245**:77-85.

DOI: 10.1016/j.mce.2005.10.008

jbc.M104744200

jbc.M110.216200

jbc.M403997200

me.2013-1379

molcel.2010.01.004

[14] Huang ZJ, Edery I, Rosbash M. PAS is a dimerization domain common to Drosophila period and several transcription factors. Nature. 1993;**364**:259-262. DOI:

[15] Chang CY, Norris JD, Grøn H, Paige LA, Hamilton PT, Kenan DJ, et al. Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries: Discovery of peptide antagonists of estrogen receptors alpha and beta. Molecular and Cellular Biology.

**64**

[27] Tilli MT, Reiter R, Oh AS, Henke RT, McDonnell K, Gallicano GI, et al. Overexpression of an N-terminally truncated isoform of the nuclear receptor coactivator amplified in breast cancer 1 leads to altered proliferation of mammary epithelial cells in transgenic mice. Molecular Endocrinology. 2005;**19**:644-656. DOI: 10.1210/ me.2004-0106

[28] Nakles RE, Shiffert MT, Díaz-Cruz ES, Cabrera MC, Alotaiby M, Miermont AM, et al. Altered AIB1 or AIB1Δ3 expression impacts ERα effects on mammary gland stromal and epithelial content. Molecular Endocrinology. 2011;**25**:549-563. DOI: 10.1210/ me.2010-0114

[29] Louie MC, Revenko AS, Zou JX, Yao J, Chen HW. Direct control of cell cycle gene expression by proto-oncogene product ACTR, and its autoregulation underlies its transforming activity. Molecular and Cellular Biology. 2006;**26**:3810-3823. DOI: 10.1128/ MCB.26.10.3810-3823.2006

[30] Li JV, Chien CD, Garee JP, Xu J, Wellstein A, Riegel AT. Transcriptional repression of AIB1 by FoxG1 leads to apoptosis in breast cancer cells. Molecular Endocrinology. 2013;**27**:1113-1127. DOI: 10.1210/ me.2012-1353

[31] Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S, et al. Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3. Cell Death and Disease. 2016;**7**:e2463-e2463. DOI: 10.1038/ cddis.2016.367

[32] Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Molecular and Cellular Biology. 2006;**26**:8191- 8201. DOI: 10.1128/MCB.00242-06

[33] Wu R-C, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell. 2007;**129**:1125-1140. DOI: 10.1016/j.cell.2007.04.039

[34] Li C, Liang Y-Y, Feng X-H, Tsai SY, Tsai M-J, O'Malley BW. Essential phosphatases and a phospho-degron are critical for regulation of SRC-3/ AIB1 coactivator function and turnover. Molecular Cell. 2008;**31**:835-849. DOI: 10.1016/j.molcel.2008.07.019

[35] Wu R-C, Qin J, Yi P, Wong J, Tsai SY, Tsai M-J, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Molecular Cell. 2004;**15**:937-949. DOI: 10.1016/j.molcel.2004.08.019

[36] York B, Yu C, Sagen JV, Liu Z, Nikolai BC, Wu R-C, et al. Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology. Proceedings of the National Academy of Sciences of the United States of America. 2010;**107**:11122-11127. DOI: 10.1073/pnas.1005262107

[37] Oh A, List H-J, Reiter R, Mani A, Zhang Y, Gehan E, et al. The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells. Cancer Research. 2004;**64**:8299-8308. DOI: 10.1158/0008- 5472.CAN-04-0354

[38] Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Molecular and Cellular Biology. 2008;**28**:6580-6593. DOI: 10.1128/MCB.00118-08

[39] Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in

transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;**387**:733-736. DOI: 10.1038/42750

[40] Zhou XE, Suino-Powell KM, Li J, He Y, Mackeigan JP, Melcher K, et al. Identification of SRC3/AIB1 as a preferred coactivator for hormoneactivated androgen receptor. The Journal of Biological Chemistry. 2010;**285**:9161-9171. DOI: 10.1074/jbc. M109.085779

[41] Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. Proceedings of the National Academy of Sciences of the United States of America. 2004;**101**:11599-11604. DOI: 10.1073/ pnas.0402997101

[42] Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/ neu in tamoxifen resistance in breast cancer. JNCI Journal of the National Cancer Institute. 2003;**95**:353-361

[43] Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Research and Treatment. 2009;**116**:225-237. DOI: 10.1007/ s10549-009-0405-2

[44] Bautista S, Vallès H, Walker RL, Anzick S, Zeillinger R, Meltzer P, et al. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity. Clinical Cancer Research. 1998;**4**:2925-2929

[45] Bouras T, Southey MC, Venter DJ. Overexpression of the steroid receptor coactivator AIB1 in breast cancer correlates with the absence of estrogen and progesterone receptors and positivity for p53 and HER2/neu. Cancer Research. 2001;**61**:903-907

[46] Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN. Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer. 2001;**85**:1928-1936. DOI: 10.1054/bjoc.2001.2179

[47] Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel AT. Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Research. 2007;**67**:7256-7265. DOI: 10.1158/0008-5472.CAN-07-1013

[48] Fereshteh MP, Tilli MT, Kim SE, Xu J, O'Malley BW, Wellstein A, et al. The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice. Cancer Research. 2008;**68**:3697-3706. DOI: 10.1158/0008-5472.CAN-07-6702

[49] Laviola L, Natalicchio A, Giorgino F. The IGF-I signaling pathway. Current Pharmaceutical Design. 2007;**13**:663-669

[50] Kuang S-Q, Liao L, Zhang H, Lee AV, O'Malley BW, Xu J. AIB1/ SRC-3 deficiency affects insulin-like growth factor I signaling pathway and suppresses v-Ha-ras-induced breast cancer initiation and progression in mice. Cancer Research. 2004;**64**:1875-1885

[51] Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, Brown M. Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. Cancer Research. 2006;**66**:11381- 11388. DOI: 10.1158/0008-5472. CAN-06-2316

[52] Eferl R, Wagner EF. AP-1: A doubleedged sword in tumorigenesis. Nature Reviews. Cancer. 2003;**3**:859-868. DOI: 10.1038/nrc1209

**67**

*The AIB1/NCOA3/SRC-3 Oncogene*

[54] Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/ AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Letters. 2008;**261**:64-73. DOI: 10.1016/j.

[55] Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Research. 2008;**68**:5460-5468. DOI: 10.1158/0008-5472.CAN-08-0955

[56] Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML. TEAD/ TEF transcription factors utilize the activation domain of YAP65, a Src/ Yes-associated protein localized in the cytoplasm. Genes & Development. 2001;**15**:1229-1241. DOI: 10.1101/

[57] Stein C, Bardet AF, Roma G, Bergling S, Clay I, Ruchti A, et al. YAP1 exerts its transcriptional control

via TEAD-mediated activation of enhancers. PLoS Genetics.

10.1016/j.ccell.2016.05.005

10.1016/j.celrep.2015.12.104

[59] Liu X, Li H, Rajurkar M, Li Q, Cotton JL, Ou J, et al. Tead and AP1 coordinate transcription and motility. Cell Reports. 2016;**14**:1169-1180. DOI:

2015;**11**:e1005465. DOI: 10.1371/journal.

[58] Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;**29**:783-803. DOI:

canlet.2007.11.013

gad.888601

pgen.1005465

*DOI: http://dx.doi.org/10.5772/intechopen.80925*

[60] Kim T, Hwang D, Lee D, Kim JH, Kim S-Y, Lim D-S. MRTF potentiates TEAD-YAP transcriptional activity causing metastasis. The EMBO Journal.

[61] Zhang C, Robinson BS, Xu W, Yang L, Yao B, Zhao H, et al. The ecdysone receptor coactivator Taiman links Yorkie to transcriptional control of germline stem cell factors in somatic tissue. Developmental Cell. 2015;**34**:168-180. DOI: 10.1016/j.devcel.2015.05.010

[62] Zanconato F, Forcato M, Battilana G, Azzolin L, Quaranta E, Bodega B, et al. Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth. Nature Cell Biology. 2015;**17**:1218-1227. DOI:

[63] Kim T, Yang S-J, Hwang D, Song J, Kim M, Kyum Kim S, et al. A basal-like breast cancer-specific role for SRF-IL6 in YAP-induced cancer stemness. Nature Communications. 2015;**6**:1309. DOI:

[64] Esnault C, Stewart A, Gualdrini F, East P, Horswell S, Matthews N, et al. Rho-actin signaling to the MRTF coactivators dominates the immediate transcriptional response to serum in fibroblasts. Genes & Development. 2014;**28**:943-958. DOI: 10.1101/

[65] O'Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nature Reviews. Clinical Oncology. 2016;**13**:417-430. DOI: 10.1038/nrclinonc.2016.26

[66] Dimova DK, Dyson NJ. The E2F transcriptional network: Old acquaintances with new faces. Oncogene. 2005;**24**:2810-2826. DOI:

10.1038/sj.onc.1208612

[67] Mussi P, Yu C, O'Malley BW, Xu J. Stimulation of steroid

2017;**36**:520-535. DOI: 10.15252/

embj.201695137

10.1038/ncb3216

10.1038/ncomms10186

gad.239327.114

[53] Yan J, Yu CT, Ozen M, Ittmann M, Tsai SY, Tsai MJ. Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Research. 2006;**66**:11039-11046. DOI: 10.1158/0008-5472.CAN-06-2442
